AI Issuer Brief
Arphra AILoading cached brief…
Peers
No peer list available for INSM.
Price change · trailing returns
Live · FMP| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.35% | -0.84% | -21.58% | -28.41% | -48.54% | -38.57% | +49.15% | +461.80% | +324.75% | +806.02% | -35.21% |
Aftermarket
Live · FMPLast trade
$106.91
60 sh
Bid
$105.80
1 sh
Ask
$110.00
10 sh
Spread
$4.200
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $213.11 (+99.34%)
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Insmed Incorporated (INSM) Presents at Bank of America Global Healthcare Conference 2026 Transcriptseekingalpha.com·May 12, 2026
- Insmed Reports First-Quarter 2026 Financial Results and Provides Business Updateprnewswire.com·May 07, 2026
- Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasisprnewswire.com·May 06, 2026
- Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026prnewswire.com·May 04, 2026
- Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026prnewswire.com·May 04, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|